Merck Gains FDA Label Update for WINREVAIR in PAH
RAHWAY, N.J. — September 22, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has approved an...
Cardiovascular
Advertisement
Milestone Enrolls First Canadian Patient in ReVeRA-301
MONTREAL and CHARLOTTE, N.C. — September 24, 2026 Milestone Pharmaceuticals Inc. announced that the Montreal Heart Institute has enrolled...
Roche Opens Boston Innovation Center for CVRM Research
BASEL, Switzerland — September 17, 2026 Roche announced the grand opening of the Roche Genentech Innovation Center Boston, expanding...
United Therapeutics Reports Phase 3 Ralinepag Results in The Lancet
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 29, 2026 United Therapeutics Corporation announced that the complete results...
Humacyte FDA Accepts IND for First-in-Human CTEV CABG Study
DURHAM, N.C., July 27, 2026 Humacyte, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Advertisements
Tenax Therapeutics to Present LEVEL Phase 3 Data at ESC
CHAPEL HILL, N.C., July 2, 2026 Tenax Therapeutics, Inc. announced that results from its Phase 3 LEVEL clinical trial...
Artivion Secures FDA Approval for NEXUS Aortic System
ATLANTA, Georgia, United States, April 7, 2026 Artivion, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Bristol Myers Squibb Reports New Camzyos Data at ACC
PRINCETON, NEW JERSEY, March 23, 2026 Bristol Myers Squibb has unveiled new clinical and real-world data for Camzyos (mavacamten)...
CND Life Sciences’ Syn-One® Biomarker Services Advance Parkinson’s Research in Phase 2 Clinical Trial
PHOENIX, AZ – November 11, 2025 — CND Life Sciences, a pioneering neurodiagnostic company, announced that its Syn-One® Biomarker...
Cytokinetics Presents New MAPLE-HCM Data at AHA 2025, Strengthening Pipeline in Rare Cardiomyopathy Therapy
San Francisco, November 10, 2025 — Cytokinetics, Inc., a biopharmaceutical company focused on developing muscle biology–driven therapies, announced the...
Advertisement
